Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology · Chronic Myeloid Leukemia

Monitoring Your Health: Symptoms and Red Flags

At a Glance

Most CML symptoms and treatment side effects are manageable, but fever, worsening breathing, severe abdominal pain, unusual bleeding, sudden weakness or confusion, chest pressure, or blue lips require prompt or emergency medical care.

Managing Chronic Myeloid Leukemia (CML) involves distinguishing between the expected “nuisance” symptoms of the disease or its treatment and the rare but serious “red flags” that require immediate medical attention. Most people with CML live stable, active lives on Tyrosine Kinase Inhibitor (TKI) therapy, but being an informed advocate for your own health means knowing when to call your care team and when to seek emergency help.

Common Symptoms and Expected Side Effects

In the early stages of CML, symptoms are often mild and non-specific. Many patients experience fatigue, a feeling of “fullness” in the upper-left abdomen (due to an enlarged spleen), or night sweats [1][2].

Once you start TKI therapy, you may experience side effects as your body adjusts to the medication. These are common and usually manageable, but severe or persistent symptoms (like persistent vomiting, worsening rash, jaundice, or severe diarrhea) should prompt an earlier call rather than waiting for your next appointment:

  • Gastrointestinal Issues: Diarrhea is particularly common with bosutinib, while nausea or vomiting can occur with most TKIs [3][4].
  • Skin and Hair: Mild rashes, itching (pruritus), or slight hair thinning (alopecia) are frequently reported [5].
  • Fluid Retention: Swelling around the eyes or in the ankles is a known side effect, especially with imatinib or dasatinib [6].
  • Muscle and Joint Pain: Aches in the bones or joints (arthralgia) can occur, particularly when first starting treatment [7].

Urgent Symptoms: Call Your Care Team Same-Day

Some symptoms require a prompt evaluation (usually within 24 hours) to prevent them from becoming more serious:

  • Fever and Infection: TKIs can cause neutropenia (low healthy white blood cells). Ask your team for a specific fever threshold (often 100.4°F/38°C). Fever, chills, or a severe sore throat require urgent evaluation.
  • Worsening Shortness of Breath: If you find yourself more winded than usual during light activity, or if you have new or rapidly worsening swelling/weight gain, it could signal pleural effusion (fluid around the lungs) or pulmonary arterial hypertension, which are known risks of dasatinib [8][9].
  • Severe Abdominal Pain: Intense pain in the upper abdomen that may radiate to the back, especially if accompanied by vomiting, can indicate pancreatitis (inflammation of the pancreas). This is a documented risk with asciminib and ponatinib [10].
  • Unusual Bleeding or Bruising: Nosebleeds that won’t stop, bleeding gums, or large “unexplained” bruises may indicate thrombocytopenia (a dangerously low platelet count) caused by the medication’s effect on your bone marrow [11].

Emergency Red Flags: Seek Immediate Care

The following symptoms represent rare but life-threatening complications. If you experience any of these, call emergency services or go to the nearest emergency room immediately. Make sure you have your oncology after-hours number saved.

1. Leukostasis (White Cell “Sludging”)

In very rare cases, extremely high white blood cell counts can cause the blood to become thick and block small blood vessels. There is no reliable numerical cutoff; it is symptom-based [12].

  • Neurological: Sudden confusion, severe headache, double vision, or difficulty hearing [13][14].
  • Respiratory: Severe, sudden difficulty breathing or a “gasping” for air [15].

2. Arterial Occlusive Events (Vascular Blockages)

Some TKIs, specifically nilotinib and ponatinib, are associated with a higher risk of sudden blockages in the arteries [7][10].

  • Stroke/TIA: Sudden numbness or weakness on one side of the body, facial droop, or trouble speaking [16].
  • Heart Attack: Sudden chest pressure, pain radiating to the jaw or left arm, and cold sweats [P-109].
  • Acute Limb Ischemia: A leg or arm that suddenly becomes very painful, cold to the touch, pale, or numb [P-110].

3. Severe Respiratory Failure or Uncontrolled Bleeding

While mild fluid retention is common, a massive pleural effusion can cause a total inability to breathe comfortably even while resting. If you cannot catch your breath or your lips/fingernails appear blue, this is an emergency [17][18]. Severe allergic symptoms or uncontrolled bleeding also require immediate 911 care.

Common questions in this guide

What CML treatment side effects are common?
Diarrhea, nausea or vomiting, mild rash or itching, slight hair thinning, swelling, and muscle or joint aches can occur with tyrosine kinase inhibitors. They are often manageable, but persistent vomiting, a worsening rash, yellowing of the skin or eyes, severe diarrhea, or rapidly increasing swelling should prompt a call to your care team.
When should I call my CML care team about a fever?
Tyrosine kinase inhibitor treatment can lower healthy white blood cells, making infection more concerning. Call your team promptly for fever, chills, or a severe sore throat, and ask what threshold to use because 100.4°F (38°C) is often used.
When does shortness of breath require urgent or emergency care?
New or worsening shortness of breath, especially with new swelling or rapid weight gain, can signal fluid around the lungs or another serious complication. Contact your care team the same day for worsening symptoms. If you cannot catch your breath at rest or your lips or fingernails turn blue, seek emergency help immediately.
Could severe abdominal pain be a CML treatment emergency?
Severe upper-abdominal pain that may spread to the back, especially with vomiting, can be a sign of pancreatitis, or inflammation of the pancreas. This risk is associated with medicines such as asciminib and ponatinib, so seek same-day medical advice rather than waiting for a routine visit.
Which sudden neurological or cardiovascular symptoms are CML emergencies?
Sudden confusion, a severe headache, double vision, difficulty hearing, or sudden gasping for air can be signs of a rare emergency related to very high white blood cell counts. Sudden one-sided weakness or numbness, facial drooping, trouble speaking, chest pressure, or pain spreading to the jaw or arm can signal a stroke or heart attack. Call emergency services immediately.
What bleeding or bruising symptoms need urgent attention?
Bleeding that will not stop, bleeding gums, nosebleeds, or large unexplained bruises may reflect a very low platelet count. Contact your care team urgently, and seek emergency care for uncontrolled or severe bleeding.
What should I track at home while monitoring CML?
Track your usual activity, fatigue, breathing, weight, blood pressure, swelling, and other symptoms so you can recognize a change. Keep your oncology team's contact information and after-hours number available, and ask which changes or blood-count results should trigger a call.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are the 'safe ranges' for my specific blood counts, and at what exact number should I call your office?
  2. 2.Given my choice of TKI, what specific cardiovascular or pulmonary screenings (like EKGs or echocardiograms) will I need and how often?
  3. 3.If I experience mild side effects like diarrhea or a rash, what over-the-counter or prescription options do you recommend I have on hand?
  4. 4.How do we distinguish between 'normal' fatigue from CML and more serious shortness of breath related to my medication?
  5. 5.What is our plan for monitoring my pancreas and liver health while I am on this treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Chronic Myeloid Leukemia: A Review.

    Jabbour E, Kantarjian H

    JAMA 2025; (333(18)):1618-1629 doi:10.1001/jama.2025.0220.

    PMID: 40094679
  2. 2

    Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Deininger MW, Shah NP, Altman JK, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(10)):1385-1415.

    PMID: 33022644
  3. 3

    Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.

    Hochhaus A, Gambacorti-Passerini C, Abboud C, et al.

    Leukemia 2020; (34(8)):2125-2137 doi:10.1038/s41375-020-0915-9.

    PMID: 32572189
  4. 4

    Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.

    Kota V, Brümmendorf TH, Gambacorti-Passerini C, et al.

    Leukemia research 2021; (111()):106690 doi:10.1016/j.leukres.2021.106690.

    PMID: 34673442
  5. 5

    Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.

    Cha SH, Kim K, Song YK

    Acta oncologica (Stockholm, Sweden) 2023; (62(12)):1767-1774 doi:10.1080/0284186X.2023.2263152.

    PMID: 37787749
  6. 6

    Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report.

    Maat Z, Mushtaq K, Yassin MA

    Case reports in oncology 2021; (14(3)):1441-1446 doi:10.1159/000516794.

    PMID: 34899234
  7. 7

    Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

    Iurlo A, Orsi E, Cattaneo D, et al.

    Oncotarget 2015; (6(32)):33944-51 doi:10.18632/oncotarget.5580.

    PMID: 26376678
  8. 8

    Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.

    Weatherald J, Chaumais MC, Montani D

    Current opinion in pulmonary medicine 2017; (23(5)):392-397 doi:10.1097/MCP.0000000000000412.

    PMID: 28639957
  9. 9

    Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice.

    Gürdoğan M, Demir M, Yalta K, Gülertop Y

    Anatolian journal of cardiology 2023; (27(6)):299-307 doi:10.14744/AnatolJCardiol.2023.3013.

    PMID: 37257013
  10. 10

    Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

    Cortes JE, Kim DW, Pinilla-Ibarz J, et al.

    Blood 2018; (132(4)):393-404 doi:10.1182/blood-2016-09-739086.

    PMID: 29567798
  11. 11

    Adverse reactions of dasatinib in pediatric acute lymphoblastic leukemia: a retrospective comparative cohort study.

    Yu LT, Xue Q, Feng Q, et al.

    Translational pediatrics 2025; (14(11)):3002-3010 doi:10.21037/tp-2025-403.

    PMID: 41367522
  12. 12

    How I treat hyperleukocytosis in acute myeloid leukemia.

    Röllig C, Ehninger G

    Blood 2015; (125(21)):3246-52 doi:10.1182/blood-2014-10-551507.

    PMID: 25778528
  13. 13

    Intracerebral hemorrhage as the first symptomatic manifestation of chronic myeloid leukemia (chronic phase): A case report and literature review.

    Ashraf M, Naseeruddin G, Zahra SG, et al.

    Surgical neurology international 2023; (14()):5 doi:10.25259/SNI_897_2022.

    PMID: 36751457
  14. 14

    Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group.

    Kurosawa H, Tanizawa A, Tono C, et al.

    Pediatric blood & cancer 2016; (63(3)):406-11 doi:10.1002/pbc.25803.

    PMID: 26485422
  15. 15

    Intraoperative Collapse During First-Trimester Abortion: Hyperleukocytosis Crisis, Thrombotic Pulmonary Embolism, or Amniotic Fluid Embolism?

    Wen T, Zhang Y, Zhong Y, Song S

    International journal of women's health 2026; (18()):604225 doi:10.2147/IJWH.S604225.

    PMID: 42519500
  16. 16

    Vertebral artery stenosis predicts cerebrovascular diseases following radiotherapy for nasopharyngeal carcinoma.

    Yeh CF, Chin YC, Hung W, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(7)):5821-5830 doi:10.1007/s00520-022-07011-8.

    PMID: 35357575
  17. 17

    Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.

    Satoh K, Morisawa S, Okuyama M, Nakae H

    BMJ case reports 2021; (14(9)) doi:10.1136/bcr-2021-243671.

    PMID: 34479888
  18. 18

    Multidisciplinary Rehabilitation for Severe Respiratory Failure Due to Dasatinib-Induced Pulmonary Toxicity: A Case Report.

    Nozaki K, Hamazaki N, Takeshita Y, et al.

    The American journal of case reports 2026; (27()):e953380 doi:10.12659/AJCR.953380.

    PMID: 42424244

This page is for informational purposes only and does not constitute medical advice. Ask your oncology team how to respond to symptoms or side effects, and seek emergency care for severe warning signs.

Get notified when new evidence is published on Philadelphia-positive myelogenous leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.